Aurobindo Pharma rose nearly 3% after its subsidiary, Eugia Pharma, got the USFDA approval to make and market Dasatinib Tablets, a leukaemia drug with a $1.8 billion market.
Aurobindo Pharma rose nearly 3% after its subsidiary, Eugia Pharma, got the USFDA approval to make and market Dasatinib Tablets, a leukaemia drug with a $1.8 billion market.